DexCom, Inc. (NASDAQ:DXCM) Shares Acquired by Jennison Associates LLC

Jennison Associates LLC boosted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 10.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,643,757 shares of the medical device company’s stock after purchasing an additional 710,858 shares during the period. Jennison Associates LLC owned approximately 1.96% of DexCom worth $594,455,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Versant Capital Management Inc purchased a new position in DexCom in the 4th quarter valued at about $25,000. Riverview Trust Co lifted its stake in shares of DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after acquiring an additional 232 shares in the last quarter. Heck Capital Advisors LLC purchased a new position in DexCom in the fourth quarter valued at about $38,000. MassMutual Private Wealth & Trust FSB grew its stake in DexCom by 46.7% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock valued at $65,000 after purchasing an additional 265 shares in the last quarter. Finally, RPg Family Wealth Advisory LLC purchased a new stake in DexCom during the 3rd quarter worth approximately $57,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Wall Street Analysts Forecast Growth

DXCM has been the subject of several research analyst reports. JPMorgan Chase & Co. increased their target price on DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research note on Friday, October 25th. Leerink Partners decreased their price objective on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Redburn Atlantic raised shares of DexCom from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $85.00 to $115.00 in a research report on Monday. Citigroup increased their price target on shares of DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Finally, Royal Bank of Canada decreased their price target on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $98.41.

DexCom Stock Performance

Shares of DXCM opened at $86.83 on Monday. The firm has a fifty day moving average of $80.77 and a 200-day moving average of $76.21. The company has a market cap of $33.92 billion, a price-to-earnings ratio of 51.99, a price-to-earnings-growth ratio of 2.23 and a beta of 1.14. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00.

Insider Buying and Selling at DexCom

In related news, EVP Jereme M. Sylvain sold 2,090 shares of the company’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the sale, the executive vice president now owns 83,526 shares of the company’s stock, valued at $7,259,244.66. This represents a 2.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the transaction, the chief executive officer now owns 319,037 shares of the company’s stock, valued at $27,727,505.67. This represents a 9.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 42,342 shares of company stock valued at $3,628,069 in the last ninety days. Company insiders own 0.30% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.